Pharma marketers enter 2026 asking where DTC fits in the DTP era.  | Pharma marketers enter 2026 asking where DTC fits in the DTP era. That question, which few foresaw 12 months ago, reflects the fast rise of direct-to-patient programs.

The U.S. pharmaceutical industry in 2025 remains one of the nation’s most dynamic and profitable economic sectors.

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of the respondents say they see the same number of pharma ads as they did last year, while 42% indicate they see more this year.

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory conditions. The target applies to a range of potential indications, from cardiovascular, metabolic, rheumatic, dermatologic and rare genetic diseases.

Discover why Syndax Pharmaceuticals (SNDX) is a strong buy, with FDA approvals, sales set to double by 2026, and major long-term growth potential.

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.

DGFT's floor prices on select bulk drugs aim to curb Chinese dumping, support PLI-backed manufacturers and lift domestic offtake, though capped medicine prices may limit cost pass-through

The Council and the Parliament have reached a deal on new rules to make the EU’s pharmaceutical sector fairer and more competitive.

Google’s policy update expands pharmaceutical advertising access in programmatic channels and shifts greater compliance risk to advertisers.

The average one-year price target for OKYO Pharma (NasdaqCM:OKYO) has been revised to $8.50 / share. This is a decrease of 16.67% from the prior estimate of $10.20 dated December 3, 2025. The price target is an average of many targets provided by analysts.